Figure 5 from the Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance Mandy Lawson , Natalie Cureton , Susana Ros , Azadeh Cheraghchi-Bashi , Jelena Urosevic , Sophie D'Arcy , Oona Delpuech , Michelle DuPont , David I. Fisher , Eric T. Gangl , Hilary Lewis , Dawn Trueman , Neha Wali , Stuart C. Williamson , Jennifer Moss , Elodie Montaudon , Heloise Derrien , Elisabetta Marangoni , Ricardo J. Miragaia , Sladjana Gagrica , Pablo Morentin-Gutierrez , Thomas A. Moss , Gareth Maglennon , Daniel Sutton , Radoslaw Polanski , Alan Rosen , Jonathan Cairns , Pei Zhang , Mònica Sánchez-Guixé , Violeta Serra , Susan E. Critchlow , James S. Scott , Justin P.O. Lindemann , Simon T. Barry , Teresa Klinowska , Christopher J. Morrow , Larissa S Carnevalli crossref（2023）
Key words
CDK4/6 Inhibitors
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
